Adial CEO to Present at the Spring MicroCap Rodeo Conference on June 6th
GLEN ALLEN, Va., May 29, 2024 (GLOBE NEWSWIRE) — Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will be participating in the Spring MicroCap Rodeo Conference that will be held on Thursday, June 6, 2024 in New York City.
Cary Claiborne, President and Chief Executive Officer of Adial, is scheduled to present at 2:00 p.m. Eastern Time on Thursday, June 6th. The presentation will be webcast live and available at https://www.webcaster4.com/Webcast/Page/3045/50687 as well as on the Company’s investor relations section of the website at www.adial.com/events.
Management will also be hosting 1×1 meetings throughout the conference with approved investors.
Information and registration for the conference can be found here at MicroCap Rodeo.
About the MicroCap Rodeo Conference
The MicroCap Rodeo Conferences are unique, as they are run by money managers and investors for money managers and investors. For the “Spring into Summer Conference”, it will be hosted live in New York City on Thursday, June 6th. The executive management teams of approximately 25+ MicroCap companies across a wide swath of industries will be participating in the conference. Investors will be able to harness top stock ideas for their portfolios by participating in group presentations, as well as 1x1s, in order to garner an understanding into the key value drivers and potential trends for the 2H of 2024 and beyond. There will also be industry guest speakers as well as networking opportunities throughout the conference. For more information please contact info@microcaprodeo.com
About Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company’s ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company’s companion diagnostic genetic test. ONWARD showed promising results in reducing drinking in heavy drinking patients, and no overt safety or tolerability concerns. AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Additional information is available at www.adial.com.
Contact:
Crescendo Communications, LLC
David Waldman / Alexandra Schilt
Tel: 212-671-1020
Email: adil@crescendo-ir.com
